English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Serratiopeptidase is an anti inflammatory enzyme commonly used in the treatment of various inflammatory disorders. It is found to have no GI related side effects unlike NSAIDs and can be safely used for chronic conditions. Formulations of controlled release tablets can decrease the frequency of administration and thereby improve the patient compliance. As Serratiopeptidase is acid-liable, it is made into enteric dispersion with the polymer viz. Eudragit L 100 by solvent evaporation technique. The polymer is used in various proportions and the optimum solid dispersion was selected based on the drug release study for enteric products. The controlled release tablets of the Serratiopeptidase solid dispersion were prepared with the polymers viz. ethyl cellulose, hydroxypropylmethylcellulose and methylcellulose in various proportions. Drug release study was conducted for 6 hours in pH 6.8 phosphate buffer. The formulation containing ethyl cellulose in 125 mg quantity showed drug release in controlled manner upto 6 hours.

Enteric dispersion or Serratiopeptidase with Eudragit L100 and Formulation of Controlled Release Tablets of Serratiopeptidase